BIAF

BioAffinity Technologies Inc. (BIAF) | Rumor.io

BioAffinity Technologies

BIAF

Attention (50-day avg)0.01%

Attention rank (50-day avg)#461

Bullish sentiment (50-day avg)79%

Price to earnings ratio-0.06

Market capitalization4.5M

Earnings per share-1.35

Dividend yield (TTM)—

Revenue (annual)6.1M

Net income (annual)-14.9M

Social

What share of all stock conversation is about BIAF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0.01% +0.01	0% 0

Sep 22

bioAffinity Technologies is set to present positive clinical and veteran-focused data on CyPath Lung at the NAVREF 2026 Annual Conference.
The company's data presentation demonstrates the beneficial role of CyPath Lung in veteran lung cancer care.
bioAffinity Technologies' stock price has increased significantly, with some posts mentioning a +15.4% gain and a volume of 12.6x.

Generated by AI

Sentiment

Of the messages about BIAF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +35.66	78.94% -2.87	85.87% +4.43
Bearish	0%	0% -35.66	21.06% +2.87	14.13% -4.43

Bullish· Sep 18

The asset has a strong potential for continued growth, with some analysts predicting a price target of $18, and the current price being $10.50.
The company has shown resilience and strength in the market, with the stock closing above its 50-day and 200-day moving averages on the daily and 4-hour charts.
The asset's price movement has been characterized by significant gains, with a 112% overnight swing and a 46% gain on a particular trade, indicating a high level of volatility and potential for further growth.

Bearish· Sep 17

The stock's price is highly volatile, with a 70% increase in a short period, making it difficult to predict its trajectory.
The company's patent-driven growth is unsustainable, as evidenced by the stock's rapid decline after the patent was sold down.
The stock's high short interest and the involvement of a hedge fund shorting the stock suggest a bearish sentiment among market participants.

Generated by AI

Topics

Of the messages about BIAF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	31.65%	49.11%
Technical Analysis	—	0%	29.37%	24.82%
Analysts	—	0%	25.5%	9.4%
Macro	—	0%	13.1%	15.71%
Earnings	—	0%	0%	0.32%
Controversies	—	0%	0.4%	0.64%

Announcements· Sep 17

bioAffinity Technologies, Inc. (BIAF) announced the grant of a Hong Kong patent for its CyPath Lung noninvasive lung cancer diagnostic, expanding intellectual property protection in a key market.
The patent approval may support the company's competitive positioning and potential licensing or intellectual property value realization.
The Hong Kong patent grant is the latest in a series of patent approvals, following a 2025 China patent, and builds out the company's intellectual property coverage across Asia.

Technical Analysis· Sep 2

The current trade in $BIAF is being watched closely, with a potential breakout level needed to confirm the trade; the stock has remained a session-after-session momentum name, with volume pouring in and price holding above $1.50.
A trading plan for $BIAF has been outlined, with an entry price of $9.91, 1st price target of $10.60, and 2nd price target of $11.30; a stop loss has been set at $9.22.
$BIAF is being closely watched for a potential gap at $13-$14, with a cup and handle pattern identified; a strong move up or down is expected due to the bull flag squeeze, making this area key for a major breakout.

Generated by AI

Community

Of the messages about BIAF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	25.81%	40.45%	32.22%
Newcomers	100%	74.19%	59.55%	67.78%

Regulars· Sep 18

The stock price of bioAffinity Technologies, Inc. ($BIAF) surged by 34.74% to $11.79 in Friday trading, primarily due to the grant of a Hong Kong patent for its CyPath Lung noninvasive lung cancer diagnostic.
The CyPath Lung diagnostic has the potential to improve the chances of both survival and a high quality of life by identifying more pulmonary nodules and providing real-time information in cases where imaging leaves questions unanswered.
The stock price of $BIAF has shown significant gains, with some regulars reporting overnight swings of 112% and 46%, and is expected to continue its upward trend with the next catalyst being a potential licensing agreement with immediate lump sum and milestone payments.

Newcomers· Sep 22

Newcomers are focusing on the technical analysis of bioAffinity Technologies, Inc. ($BIAF), with some noting a potential "wall of resistance" at $9 and others observing a short setup with a 12.6x increase in volume.
Others are analyzing the company's recent performance, with some noting a big sell-off and others speculating about potential good news.
There is also discussion about the company's presentation at the NAVREF 2026 Annual Conference, with some questioning the significance of the news and others speculating about its potential impact on the stock price.

Generated by AI

bioAffinity Technologies (NASDAQ:BIAF) is continuing to build momentum behind its non-invasive lung cancer diagnostic, CyPath Lung, with new clinical evidence and an expanding route into the US federal healthcare market. The company is presenting real-world clinical cases and new research focused on veteran and military populations at the 2026 NAVREF Annual Conference, highlighting the potential role of CyPath Lung in helping physicians make more informed diagnostic decisions.

2d agoYahoo Finance

bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference

bioAffinity Technologies (NASDAQ:BIAF) will present new clinical findings on its noninvasive lung cancer test, CyPath® Lung, at the 2026 NAVREF Annual Conference, running September 27–30 in Arlington, Virginia. The company is set to unveil two posters focused on the test’s use in veteran and military healthcare settings.

7d agoYahoo Finance

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

12d agoBenzinga

12 Health Care Stocks Moving In Thursday's Intraday Session - Aethlon Medical (NASDAQ:AEMD), bioAffinity

Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares

12d agoBenzinga

bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic

The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test.

12d agoYahoo Finance

bioAffinity Technologies Highlights Investor Presentation at Conference

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

17d agoThe Globe and Mail

Also Discussed

Investors talking about BIAF also mention

#	Name	Attention
1	Jianzhi Education Technology Group Company Limited ADRJZ	0%+0
2	STBX - Starbox Group Holdings Ltd. Ordinary Shares	——
3	Wearable Devices Ltd.WLDS	0%+0
4	Firefly Neuroscience IncAIFF	0%-0.01
5	GRFX - Graphex Group Limited	——
6	Generation Income Properties Inc.GIPR	0%0
7	Sky Quarry Inc.SKYQ	0%-0.01
8	Shuttle Pharmaceuticals Holdings, Inc.SHPH	0%0
9	GigaCloud Technology Inc Class A Ordinary SharesGCT	0%0
10	Magic Empire Global Ltd Class A Ordinary SharesMEGL	0%0

BioAffinity Technologies Inc.

Healthcare
Diagnostics & Research

BioAffinity Technologies Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other diseases of the lung. Its core offering is CyPath Lung, a laboratory-developed test that uses flow cytometry and automated analysis of sputum samples to identify cell populations associated with cancer. The company operates through two main business segments, Diagnostic Research and Development and Laboratory Services, combining test development with clinical laboratory activity. BioAffinity Technologies also works on targeted cancer therapeutics and other proprietary diagnostic platforms designed to support earlier disease detection and more precise analysis of biological samples. Based in San Antonio, Texas, BioAffinity Technologies serves the health technology and medical diagnostics market with products aimed at improving lung disease detection and diagnostic workflows.

Website

Location

3300 Nacogdoches Road

San Antonio, TX, 78217

United States

Social

What share of all stock conversation is about BIAF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0.01% +0.01	0% 0

Sep 22

bioAffinity Technologies is set to present positive clinical and veteran-focused data on CyPath Lung at the NAVREF 2026 Annual Conference.
The company's data presentation demonstrates the beneficial role of CyPath Lung in veteran lung cancer care.
bioAffinity Technologies' stock price has increased significantly, with some posts mentioning a +15.4% gain and a volume of 12.6x.

Generated by AI

Sentiment

Of the messages about BIAF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +35.66	78.94% -2.87	85.87% +4.43
Bearish	0%	0% -35.66	21.06% +2.87	14.13% -4.43

Bullish· Sep 18

The asset has a strong potential for continued growth, with some analysts predicting a price target of $18, and the current price being $10.50.
The company has shown resilience and strength in the market, with the stock closing above its 50-day and 200-day moving averages on the daily and 4-hour charts.
The asset's price movement has been characterized by significant gains, with a 112% overnight swing and a 46% gain on a particular trade, indicating a high level of volatility and potential for further growth.

Bearish· Sep 17

The stock's price is highly volatile, with a 70% increase in a short period, making it difficult to predict its trajectory.
The company's patent-driven growth is unsustainable, as evidenced by the stock's rapid decline after the patent was sold down.
The stock's high short interest and the involvement of a hedge fund shorting the stock suggest a bearish sentiment among market participants.

Generated by AI

Topics

Of the messages about BIAF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	31.65%	49.11%
Technical Analysis	—	0%	29.37%	24.82%
Analysts	—	0%	25.5%	9.4%
Macro	—	0%	13.1%	15.71%
Earnings	—	0%	0%	0.32%
Controversies	—	0%	0.4%	0.64%

Announcements· Sep 17

bioAffinity Technologies, Inc. (BIAF) announced the grant of a Hong Kong patent for its CyPath Lung noninvasive lung cancer diagnostic, expanding intellectual property protection in a key market.
The patent approval may support the company's competitive positioning and potential licensing or intellectual property value realization.
The Hong Kong patent grant is the latest in a series of patent approvals, following a 2025 China patent, and builds out the company's intellectual property coverage across Asia.

Technical Analysis· Sep 2

The current trade in $BIAF is being watched closely, with a potential breakout level needed to confirm the trade; the stock has remained a session-after-session momentum name, with volume pouring in and price holding above $1.50.
A trading plan for $BIAF has been outlined, with an entry price of $9.91, 1st price target of $10.60, and 2nd price target of $11.30; a stop loss has been set at $9.22.
$BIAF is being closely watched for a potential gap at $13-$14, with a cup and handle pattern identified; a strong move up or down is expected due to the bull flag squeeze, making this area key for a major breakout.

Generated by AI

Community

Of the messages about BIAF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	25.81%	40.45%	32.22%
Newcomers	100%	74.19%	59.55%	67.78%

Regulars· Sep 18

The stock price of bioAffinity Technologies, Inc. ($BIAF) surged by 34.74% to $11.79 in Friday trading, primarily due to the grant of a Hong Kong patent for its CyPath Lung noninvasive lung cancer diagnostic.
The CyPath Lung diagnostic has the potential to improve the chances of both survival and a high quality of life by identifying more pulmonary nodules and providing real-time information in cases where imaging leaves questions unanswered.
The stock price of $BIAF has shown significant gains, with some regulars reporting overnight swings of 112% and 46%, and is expected to continue its upward trend with the next catalyst being a potential licensing agreement with immediate lump sum and milestone payments.

Newcomers· Sep 22

Newcomers are focusing on the technical analysis of bioAffinity Technologies, Inc. ($BIAF), with some noting a potential "wall of resistance" at $9 and others observing a short setup with a 12.6x increase in volume.
Others are analyzing the company's recent performance, with some noting a big sell-off and others speculating about potential good news.
There is also discussion about the company's presentation at the NAVREF 2026 Annual Conference, with some questioning the significance of the news and others speculating about its potential impact on the stock price.

Generated by AI

BioAffinity Technologies

Social

Sep 22

Bullish· Sep 18

Bearish· Sep 17

Announcements· Sep 17

Technical Analysis· Sep 2

Regulars· Sep 18

Newcomers· Sep 22

bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection

bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

12 Health Care Stocks Moving In Thursday's Intraday Session - Aethlon Medical (NASDAQ:AEMD), bioAffinity

bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic

bioAffinity Technologies Highlights Investor Presentation at Conference

Also Discussed

BioAffinity Technologies Inc.

Company Information

Location

bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection

bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

12 Health Care Stocks Moving In Thursday's Intraday Session - Aethlon Medical (NASDAQ:AEMD), bioAffinity

bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic

bioAffinity Technologies Highlights Investor Presentation at Conference

Also Discussed

Social

Sep 22

Bullish· Sep 18

Bearish· Sep 17

Announcements· Sep 17

Technical Analysis· Sep 2

Regulars· Sep 18

Newcomers· Sep 22